Close Menu

A Biotech 'Cure'

Drugmaker GlaxoSmithKline has had a "miserable" year, says Forbes' Robert Langreth. Sales are "stagnant"; it's facing the loss of its patent on asthma drug Advair; its diabetes treatment, Avandia, is off the market in Europe and use of the drug was restricted in the US after the company was accused of minimizing data that show it caused heart problems; and in October, it paid $750 million to settle charges that it produced tainted drugs.

To read the full story....

...and receive Daily News bulletins.

Already have a GenomeWeb or 360Dx account?
Login Now.

Don't have a GenomeWeb or 360Dx account?
Register for Free.

Two COVID-19 vaccine developers have released their trial protocols to build public trust, the New York Times reports.

A new analysis finds the rapid COVID-19 test from DnaNudge to be highly accurate, Reuters reports.

In Science this week: global citizens' assembly on genome-editing technologies proposed, epigenetic markers predict metformin response, and more.

According to the Verge, many US states are not including positive results from rapid COVID-19 testing in their case numbers.